Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics
- Significant therapeutic benefit achieved whether or not patients had previously failed treatment with existing FDA-approved biological drug.
- 61-63% of patients achieved a positive HiSCR (the accepted measure of disease severity in HS).
- 67-72% of patients achieved a clinically meaningful reduction in pain.
AUSTIN, Texas, March 05, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today released findings for its Phase 2 clinical study for bermekimab presented at the American Academy of Dermatology’s annual meeting which concluded today. Held at the Walter E. Washington Convention Center in Washington, D.C., the presentation titled, “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” was provided by renown dermatologist, Dr. Alice Gottlieb, M.D., Ph.D., in the major venue Hall A. At the presentation Dr. Gottlieb provided the results for 42 HS patients that received 12 weekly injections of bermekimab therapy. Aside from excellent safety, a major finding of the study was that patients achieved significant therapeutic benefit from bermekimab therapy regardless of whether or not they had previously failed treatment with the only existing FDA-approved biological drug treatment for HS. In what the Company believes to be a breakthrough for the disease, patients having previously failed as well as those who never received anti-TNF therapy had significant reduction in pain. Pain is a hallmark of HS that has so far not been adequately addressed by any therapy.
Dr. Gottlieb showed that by week 12 of treatment, 63% of patients who have previously failed anti-TNF therapy achieved a positive HiSCR (the accepted measure of disease severity in HS); similarly, 61% of patients with no prior anti-TNF therapy achieved positive HiSCR1. These results translated into a 46% (p<0.001) and 60% (p=0.005) reduction in the number of abscesses and inflammatory nodules, respectively, for the two groups. A breakthrough finding was that 67% and 72% of patients achieved a clinically meaningful reduction in pain by week 122.The existing FDA-approved biological therapy was only shown to reduce pain when used in combination with oral antibiotics3. No antibiotics were used as part of the clinical study with bermekimab.
XBiotech’s President & CEO, John Simard, stated, “The results seen with bermekimab in HS suggest a new and important advance for the treatment of this difficult disease. The totality of results we saw presented at the AAD conference have provided compelling evidence that bermekimab could make a significant contribution to the treatment of dermatological disease.”
The study enrolled 42 patients, each receiving 400mg subcutaneous weekly doses of bermekimab in a 12-week treatment regimen. There were two treatment groups: those who had failed prior anti-TNF therapy (n=24); and those with no prior anti-TNF treatment history (n=18). The study was conducted at eleven different dermatology research centers across the U.S.
An intravenous infusion formulation of bermekimab was previously used in a randomized, double-blind, placebo controlled Phase 2 study for patients with HS, where bermekimab treated patients had a significantly higher rate of HiSCR compared to placebo. However, this was the first study of bermekimab in HS using a new subcutaneous formulation that is administered from pre-filled syringes. XBiotech invested in new filling equipment and developed the pre-filled syringe manufacturing process to provide a more convenient subcutaneous bermekimab product candidate.
Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin disorder affecting areas rich in apocrine glands. Nodules appear in the affected areas and progressively become swollen with spontaneous rupture and release of pus. This process occurs repeatedly leading to formation of deep sinus tracts and painful dermal abscesses4 ,5. Pain is a paramount condition in patients suffering from HS, as this chronic inflammation and accompanying pain account for the fact that HS is ranked first among skin disorders in terms of adversely affecting quality of life6. The global prevalence of HS is estimated at up to 4% of the population5.
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
1 HiSCR response rates at week 12 were 42% and 59% in the so called PIONEER I and PIONEER II Phase III studies with the FDA-approved drug adalimumab, respectively. Only 28% and 46% of patients achieved clinically relevant pain reduction (as defined above) in the PIONEER I and PIONEER II studies, respectively. In the PIONEER II study, patients received adalimumab as a combination therapy with antibiotics. Pain reduction results were not significant (compared to placebo) in PIONEER I.
2 The FDA accepted definition of clinically relevant pain reduction is a ≥30% reduction in the NRS pain score in patients that have also achieved a ≥1 unit reduction in pain score. Score is determined at Week 12.
3 Kimball et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016 Aug 4;375(5):422-34.
4 Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23: 985-998.
5 Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009 Apr;60(4):539-61; quiz 562-3. doi: 10.1016/j.jaad.2008.11.911.
6 Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61: 51-57.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
LGC Capital announces that it has increased its ownership to 40.4% of Little Green Pharma in Australia22.5.2019 16:25:00 CEST | Pressemelding
MONTRÉAL, May 22, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC" or the “Corporation”) announces that after much negotiation, it has successfully acquired, from a non-executive founder, additional shares in Australia’s licensed medical cannabis producer Little Green Pharma (LGP) bringing its ownership from 14.1% up to 40.4%. LGP was the first, and is currently the only, domestic cannabis company in Australia producing a locally grown medicinal cannabis medicine for patients. LGC believes the opportunity to increase its ownership in LGP creates significant value for its shareholders and enables the Corporation to further take part in the rapidly expanding Australian medical cannabis market. Little Green Pharma has had over 400 patients approved in Australia, with new patients increasing exponentially month-over-month. The Australian industry represents one of the fastest growing international medical cannabis markets globally, with approximately 6,400 SAS B f
Virtusa recognized as a Visionary in the Magic Quadrant for CRM and Customer Experience Implementation Services, Worldwide22.5.2019 16:05:00 CEST | Pressemelding
SOUTHBOROUGH, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Virtusa Corporation (NASDAQ GS:VRTU), a global provider of digital strategy, digital engineering, and IT outsourcing services that accelerates business outcomes for its clients, today announced that Gartner, Inc. has positioned Virtusa in the Visionaries Quadrant of the 2019 Magic Quadrant for CRM and Customer Experience (CX) Implementation Services, Worldwide. The report evaluated Virtusa along with 17 other companies in CRM and Customer Experience Implementation Services. Virtusa was one of only three companies to be categorized as a Visionary. According to Gartner, “The CX and CRM implementation service market is completing the shift from the implementation of core CRM technology to complex initiatives that not only transform the front office but integrate across the full enterprise’s operations. Customers now demand that organizations provide them with a continuous experience, preserving continuity of user experience across trad
InnovMetric Launches PolyWorks® Metrology Suite 201922.5.2019 15:00:00 CEST | Pressemelding
Facilitates Deployment of PolyWorks|Inspector™ in Production and Accelerates CNC CMM Measurement Sequences QUEBEC CITY, May 22, 2019 (GLOBE NEWSWIRE) -- InnovMetric Software Inc., the leading provider of universal 3D metrology software solutions, today announced the launch of the 2019 release of the PolyWorks Metrology Suite. This latest major release delivers new object measurement scripts that open the door to all the custom measurement techniques of clients within the standard PolyWorks workflow, as well as a new assisted sequencing approach that promises to greatly accelerate the time to set up CMM sequences. “Simplifying the lives of our customers while keeping them fully in control. This statement embodies the development philosophy behind the PolyWorks Metrology Suite and the latest 2019 release,” said Marc Soucy, President of InnovMetric. He added, “With its outstanding innovations that combine increased simplicity with important time savings, we are proud to bring the producti
Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid22.5.2019 12:55:00 CEST | Pressemelding
BROOKFIELD, May 22, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM) (TSX: BAM.A) (EURONEXT: BAMA) (“Brookfield”) today announced it has received approval from the Toronto Stock Exchange (“TSX”) for the renewal of its normal course issuer bid to purchase up to 82,530,440 Class A Limited Voting Shares (“Class A Shares”), representing 10% of the public float of Brookfield’s outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange (“NYSE”), and/or alternative trading systems. The period of the normal course issuer bid will extend from May 24, 2019 to May 23, 2020, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased or such other price as may be permitted. As at May 17, 2019, the number of Class A Shares issued and outstanding totalled 994,568,660, of which 825,304,404 shares represented the pub
Phenom People Launches University Recruiting, SMS & Internal Mobility Chatbot22.5.2019 10:00:00 CEST | Pressemelding
Product Innovations to Support Demand for Talent Experience Management LONDON, May 22, 2019 (GLOBE NEWSWIRE) -- Phenom People, the global leader in Talent Experience Management (TXM), has announced several new features for the Phenom Talent Experience Management platform, adding University Recruiting, SMS, WhatsApp messaging and Internal Mobility chatbot functionality to further support the demands of the new talent economy, which is undergoing major technological and societal shifts. The Phenom Talent Experience Management platform connects the interactions of the four key experiences in the talent lifecycle: candidates, recruiters, employees and management, and delivers a single platform to unify them. Cross-functional insights can be used to power a more personalised and effective experience that meets the demands of today’s talent. The Phenom Talent Experience Management platform furthers chief human resources officers’ top responsibilities across talent acquisition, talent managem
Phenom People Unveils Talent Experience Management Platform Single Platform for Every Talent Experience22.5.2019 10:00:00 CEST | Pressemelding
LONDON, May 22, 2019 (GLOBE NEWSWIRE) -- Phenom People has announced Talent Experience Management (TXM) as the holistic approach and SaaS platform to connect every interaction throughout the talent lifecycle by delivering personalised experiences. Talent Experience Management unifies technology and experience design to enhance the talent journey, transforming candidates to employees to brand advocates, while recruiters and management boost productivity and communicate seamlessly. Despite spending massive amounts of money on new investments in HR technology, today’s chief human resources officers still struggle to change the stereotype of their organisation from a cost center to a revenue generator for talent acquisition, talent management and talent evolution. With Talent Experience Management, Phenom People is helping organisations manage the new talent economy, which is undergoing major technological and societal shifts, with a solution that addresses the different needs and experien